NEWSLETTER: Nasally Delivered Dry Powder Dosage Forms: Particle Size Analysis Introduction to Nasal Delivery The delivery of APIs via nasal inhalation is of growing interest to companies looking to exploit the benefits of this delivery route. Delivery targets are typically broken down into three categories Local delivery to the nasal membranes (e.g. for vaccines, antivirals, … Read more
January 31st 2023 : Newsletter The New Year is always a time for looking ahead and 2023 will no doubt turn out to be a pivotal year in the Upperton Pharma Solutions growth story. In this Newsletter we will be previewing some of the exciting new plans that we have in store for ourselves and … Read more
18th January 2023 Upperton Pharma Solutions, a leading UK contract development and manufacturing organisation (CDMO), is delighted to announce that it has begun construction work for its new Development and GMP Manufacturing headquarters in Nottingham, UK. Working in close collaboration with its principal Design and Build contractor, T-SQUARED the team officially broke ground on the … Read more
December 21st 2022 : Newsletter Traditionally at this time of year we like to offer Season’s Greetings to all our customers and friends and whilst doing so, look back over the years at some of the highlights in what has been an exceptionally busy (and successful) year for Upperton Pharma Solutions! Here are just a … Read more
29th November 2022 – Press Release & Newsletter Upperton Pharma Solutions Appoints T-SQUARED for Design and Build of New Development and Manufacturing Facility Upperton Pharma Solutions, a leading UK contract development and manufacturing organisation (CDMO), is delighted to announce that it has appointed T-SQUARED, UK based company, as the principal Design and Build contractor for … Read more
November 16th 2022 : Newsletter Upperton has made a significant investment in ASAPprime® software and hardware to enable the company to offer its clients state of the art stability testing. This exciting new platform can be used to generate robust, accelerated chemical stability data and is now being applied at all stages of the product … Read more
September 15th 2022 : Newsletter Successful nasal drug delivery of dry powder formulations requires a delivered dose that can penetrate beyond the nasal entrance region and deposit in the peripheral nasal cavity, whilst avoiding deeper penetration to the airways of the lungs. This delivery, or deposition pattern, is determined by the aerodynamic particle size of … Read more
August 16th 2022 : Newsletter Successful MHRA Inspection Upperton is delighted to announce that during the last week of July 2022 the UK MHRA conducted a routine, three day inspection of the GMP facility and Quality Control testing laboratories following which, no Critical or Major observations were raised. Speaking after the inspection, CEO Nikki Whitfield … Read more
June 23rd 2022 : Newsletter The benefits of powder characterisation When developing products containing spray dried powders it is vital that the physical properties of the powders produced are determined. The physical properties of spray dried powders provides important information that can assist during the pre-formulation screening and early process development phases since these properties … Read more
23rd May 2022 : Press Release Upperton Pharma Solutions (Upperton), a UK-based specialist contract development and manufacturing organisation (CDMO), has announced a circa. £15m investment into the design and build of a 50,000 sq ft facility in Nottingham. The new facilities will allow a significant increase in research and development laboratory space and a 10-fold … Read more
Driven by experts,
led by science
About Us
Resources
What We Do
Development Platforms
Policies
Unit 11, Trent Gateway, Technology Drive, Beeston, Nottingham, NG9 1LA, UK. Phone: +44 (0) 115 855 7050 Email: contact@upperton.com
Copyright © 2024 Upperton Limited. All rights reserved.
To speak with a member of our team and talk about a project in more detail, set up a discovery call using the form opposite.
Download our brochure to learn more about how our capabilities and delivery approach can help you.
